Aligos Therapeutics Analyst Price Targets

Aligos Therapeutics Inc

ALGSNASDAQ

Trade with Public

$5.24

0.408.26%

最終更新: Oct 20, 10:39 AM

$4.93

0.091.86%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較株式レポート

Aligos Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aligos Therapeutics (ALGS).

Price Target Range — 6 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$43Upside to Avg. PT+720.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 28, 2026	Lake Street	Daniel Brims	Initiate	Buy	$45
May 21, 2026	Cantor Fitzgerald	Steve Seedhouse	Initiate	Overweight	$20
Mar 26, 2026	WestPark Capital	—	Initiate	Buy	$48
Mar 19, 2026	Jefferies	Anthea Li	Assumes	Buy	$60→$48
Mar 11, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$50
Jan 7, 2026	UBS	Michael Yee	Initiate	Buy	$20
Sep 12, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$50
Aug 18, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Assumes	Buy	$50
Mar 31, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$70
Mar 11, 2025	HC Wainwright & Co.	Ed Arce	PT Cut	Buy	$75→$70
Nov 7, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$75
Oct 23, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$75
Sep 20, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$75
Aug 19, 2024	HC Wainwright & Co.	Ed Arce	Initiate	Buy	$75

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $45.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Overweight rating and announces Price Target of $20.

Benzinga Newsdesk

PRO
WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

WestPark Capital initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $48.

Benzinga Newsdesk

PRO
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

Jefferies analyst Anthea Li assumes Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and lowers Price Target of $48.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Aligos Therapeutics (NASDAQ:ALGS) with a Buy and maintains $50 price target.

Benzinga Newsdesk

PRO
UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

UBS analyst Michael Yee initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $20.

Benzinga Newsdesk

Aligos Therapeutics Inc

Aligos Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

PRO
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

PRO
WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

PRO
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

PRO
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

PRO
UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

ニュース

パートナーシップ

ベンジンガ・グローバル

Aligos Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

PRO
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

PRO
WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

PRO
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

PRO
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

PRO
UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

People Also Watch

People Also Watch

Aligos Therapeutics Inc

Aligos Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

PROCantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

PROWestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

PROJefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

PROHC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

PROUBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

ニュース

パートナーシップ

ベンジンガ・グローバル

Aligos Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

PROCantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

PROWestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

PROJefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

PROHC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

PROUBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

People Also Watch

People Also Watch

PRO
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

PRO
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

PRO
WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

PRO
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

PRO
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

PRO
UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20

PRO
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45

PRO
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

PRO
WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48

PRO
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

PRO
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target

PRO
UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20